89bio
Latest round
- Series A
Last raised
- Oct 2018
Total raised
- $60M
Investors
- 4
About 89bio
, founded in 2018 and headquartered in San Francisco, US, is a clinical-stage biopharmaceutical company that specializes in the development of therapies for liver and cardiometabolic diseases. In September 2025, Roche, a portfolio company of Softbank, agreed to fully acquire 89bio, Inc.50 per share in cash. As part of the transaction 89bio, Inc.00 per share in cash, subject to achieving certain milestones. The deal was completed in October 2025. Following the transaction, the company was delisted from the NASDAQ. 89bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to address liver and cardiometabolic diseases. The company’s primary product, Pegozafermin (BIO89-100), leverages an understanding of FGF21, a master metabolic regulator, to provide potential treatment options for patients suffering from various metabolic disorders. This therapy aims to fill a critical gap in the market for patients who have limited or no approved treatment options available to them. The end-users of these therapies include patients with liver diseases and cardiometabolic conditions, with the company's products primarily marketed across North America and select international markets, targeting healthcare providers, hospitals, and specialty clinics that treat these conditions. 89bio generates revenue through strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies, focusing on B2B transactions. Revenue streams are derived from milestone payments, royalties, and potential licensing agreements related to their flagship product, Pegozafermin, as it progresses through clinical trials and prepares for market entry. The transaction structure involves upfront payments upon entering partnerships, followed by performance-based payments tied to developmental milestones, and financial returns from product sales post-commercialization. The specific pricing models for their therapies are tailored to the healthcare market, aligning with the value provided to patients and healthcare providers, ensuring accessibility while supporting the company's financial sustainability.
Who invested in 89bio
4 investors across 1 round
See all investors in 89bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 25, 2018
Amount
$60M
Investors
Questions about 89bio
Who invested in 89bio?
89bio has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has 89bio raised?
89bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did 89bio last raise money?
89bio's most recent round on record is a Series A, in Oct 2018.
What does 89bio do?
, founded in 2018 and headquartered in San Francisco, US, is a clinical-stage biopharmaceutical company that specializes in the development of therapies for liver and cardiometabolic diseases.
Where is 89bio headquartered?
89bio is headquartered in San Francisco, US.
Which VCs invest in companies like 89bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at 89bio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like 89bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.